Macro Strategist, Saxo Capital Markets

Kay Van-Petersen

Macro Strategist

Saxo Capital Markets

Thematic (Sector/Industry)

<ul><li>Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; </li><li>In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. </li></ul>

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. 

Derivatives and Quantitative Strategist

Gaudenz Schneider

Equity Bottom-Up

<ul>
<li>
Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.</li>
<li>
Highlights: Currently twelve pair trade opportunities persist across three markets and six sectors.</li>
<li>
Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.</li>
</ul>



Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.

Highlights: Currently twelve pair trade opportunities persist across three markets and six sectors.

Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.


Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (16 Mar 2026)

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare Cor (FPH AU)</a> targets a 6% return.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Health (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long ResMed (RMD AU) and short Fisher &amp; Paykel Healthcare Cor (FPH AU) targets a 6% return.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

<ul>
<li>
Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.</li>
<li>
Highlights: Currently eleven pair trade opportunities persist across three markets and six sectors.</li>
<li>
Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.</li>
</ul>



Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.

Highlights: Currently eleven pair trade opportunities persist across three markets and six sectors.

Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.


Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (2 Mar 2026)

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> targets a 5% return, with ResMed supported by cheaper valuations.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Healthcare (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long ResMed (RMD AU) and short Fisher &amp; Paykel Healthcare (FPH AU) targets a 5% return, with ResMed supported by cheaper valuations.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing.  The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Resmed Inc (RMD US)

Never Trust A Swiss Central Banker

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central...

Kay Van-Petersen

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (16 Mar 2026)

Discover twelve pair trade opportunities across three markets and six sectors using statistical mean-reversion methodology for actionable insights.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

Relative value opportunity targeting a 6% return as the healthcare spread diverges again in a pair trade with a strong track record. Ideal for...

Gaudenz Schneider

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (2 Mar 2026)

Statistical methodology identifies 11 pair trade opportunities across three markets and six sectors, offering unique insights into relative value.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...

Gaudenz Schneider

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Never Trust A Swiss Central Banker

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central...

Kay Van-Petersen

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (16 Mar 2026)

​Discover twelve pair trade opportunities across three markets and six sectors using statistical mean-reversion methodology for actionable insights.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

Relative value opportunity targeting a 6% return as the healthcare spread diverges again in a pair trade with a strong track record. Ideal for...

Gaudenz Schneider

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (2 Mar 2026)

​Statistical methodology identifies 11 pair trade opportunities across three markets and six sectors, offering unique insights into relative value.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

​Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...

Gaudenz Schneider

Discover twelve pair trade opportunities across three markets and six sectors using statistical mean-reversion methodology for actionable insights.

Statistical methodology identifies 11 pair trade opportunities across three markets and six sectors, offering unique insights into relative value.

Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...